Australia markets closed
  • ALL ORDS

    7,248.10
    -193.40 (-2.60%)
     
  • ASX 200

    6,961.60
    -177.90 (-2.49%)
     
  • AUD/USD

    0.7162
    +0.0007 (+0.09%)
     
  • OIL

    85.31
    -0.29 (-0.34%)
     
  • GOLD

    1,847.80
    -4.70 (-0.25%)
     
  • BTC-AUD

    52,589.91
    +1,862.61 (+3.67%)
     
  • CMC Crypto 200

    855.24
    +34.65 (+4.22%)
     
  • AUD/EUR

    0.6333
    +0.0009 (+0.13%)
     
  • AUD/NZD

    1.0705
    +0.0014 (+0.13%)
     
  • NZX 50

    12,185.65
    +57.44 (+0.47%)
     
  • NASDAQ

    14,149.12
    -360.46 (-2.48%)
     
  • FTSE

    7,371.46
    +74.31 (+1.02%)
     
  • Dow Jones

    34,297.73
    -66.77 (-0.19%)
     
  • DAX

    15,123.87
    +112.74 (+0.75%)
     
  • Hang Seng

    24,246.12
    +2.51 (+0.01%)
     
  • NIKKEI 225

    27,018.91
    -112.43 (-0.41%)
     

Enoyl-ACP Reductase Inhibitors Pipeline Guide 2021, Featuring Debiopharm, CrystalGenomics and Nobelex Biotech - ResearchAndMarkets.com

·3-min read

DUBLIN, December 21, 2021--(BUSINESS WIRE)--The "Enoyl-ACP Reductase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights for companies and pipeline drugs in the Enoyl-ACP reductase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

This report covers products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage products (Phase I/II and Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

The pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Infusion

  • Intradermal

  • Intramuscular

  • Intranasal

  • Intravaginal

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Enoyl-ACP reductase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Enoyl-ACP reductase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Enoyl-ACP reductase inhibitors drugs.

Enoyl-ACP reductase inhibitors Report Insights

  • Enoyl-ACP reductase inhibitors Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Enoyl-ACP reductase inhibitors Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Current Scenario and Emerging Therapies:

  • How many companies are developing Enoyl-ACP reductase inhibitors drugs?

  • How many Enoyl-ACP reductase inhibitors drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Enoyl-ACP reductase inhibitors?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Enoyl-ACP reductase inhibitors therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Enoyl-ACP reductase inhibitors and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Debiopharm

  • CrystalGenomics

  • Nobelex Biotech

Key Products

  • Afabicin (Debio 1450)

  • CG 400549

  • Debio 1452

  • Debio 1454/S

  • Debio 1453

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5z2ysm

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005720/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting